Research suggests that a new type of antipsychotic, xanomeline and trospium chloride (Cobenfy), is associated with significant improvements in cognitive symptoms among people with schizophrenia.

Pakistan will take on New Zealand in the opening match of the ODI Tri-Series. This match will be played at Gadaffi Stadium in Lahore. Pakistan is set to host South Africa and New Zealand in a Tri ...

The company successfully launched Cobenfy, a novel treatment for schizophrenia, marking a significant milestone in their neuroscience portfolio. Operational excellence and financial discipline led ...

Then I will speak to the promise we see with Cobenfy and the steady cadence of clinical data catalysts that will begin this year, further defining our future growth potential. I will end with an ...

Shares of Bristol Myers fell to $58.08. The stock is up around 25% over the past year, driven in part by investor enthusiasm for its new schizophrenia drug Cobenfy, which was approved by the FDA last ...

Bristol Myers added that it expected the U.S. approval last year of its Cobenfy treatment for patients with schizophrenia would be a driver of growth. The company also said it was expanding a ...

CHARLOTTESVILLE – UVA Health’s Blue Ridge Poison Center saw a significant drop in opioids cases and a smaller drop in THC edibles cases in 2024 compared with 2023, according to new data from ...

The top 10 biopharma M&A deals of 2023 The company is counting heavily on Cobenfy, which was approved in September and was the crown jewel of the $14 billion buyout of Karuna. BMS reported sales ...

We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company as a ...

The stock is up around 25% over the past year, driven in part by investor enthusiasm for its new schizophrenia drug Cobenfy, which was approved by the FDA last September. The new forecast draws ...

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...